linjc16/ctgov huggingface dataset:
Robotic Assisted Colon and Rectal Surgery Prognostic and Outcome Analysis

Study Overview
=================
Brief Summary
-----------------
To analysis surgical outcome between robotic and laparoscopy colon and rectal surgery. Retrospective case-control study of single institute.

Detailed Description
-----------------
Microinvasive surgery bring minor pain, faster recovery and comparable oncological outcome. Robotic surgery seems to be superior in precise dissection then before. This study compare robot assisted to laparoscopy surgery in colon and rectal disease. To analysis the surgical outcome and prognostic factors.

Official Title
-----------------
Analysis of Surgical Outcome of Robotic Surgery Versus Conventional Laparoscopy Surgery. Retrospective Case Control Study in Single Institute.

Conditions
-----------------
Colorectal Disorders

Intervention / Treatment
-----------------
* Device: robotic surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: for colon and rectal disease, using conventional laparoscopy and da Vinci Xi robot system. Exclusion Criteria: emergent operation, combined other open surgery, for non-colorectal disease, carcinomatosis found to be unsuitable for surgery once peritoneum entered, taTME in laparoscopy group and other robot system in robotic surgery group.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| conventional laparoscopy surgery<br>Conventional laparoscopy surgery for colon and rectal disease. | |
| robot assisted surgery<br>robotic assisted surgery for colon and rectal disease. | Device: robotic surgery<br>* by da Vinci Xi<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| surgical outcomes | operation time, blood loss, hospital stay, complication rate. | 2019.1.1-2022.1.8 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
robot, laparopscopy, MIS, surgical outcome, da Vinci Xi,
Glucose Monitoring in Tissue Transfers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if 1) a continuous glucose monitoring system can measure glucose levels in transferred tissue during reconstructive surgery, and 2) if glucose measurements from a continuous glucose monitoring system correlate with tissue blood perfusion.

Official Title
-----------------
Glucose Monitoring in Tissue Transfers

Conditions
-----------------
Reconstructive Tissue Surgery

Intervention / Treatment
-----------------
* Device: Continuous glucose monitoring system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of a soft tissue deformity where reconstruction with a pedicled or free tissue transfer is indicated age 18 and over ability to follow-up post-operatively Exclusion Criteria: age less than 18 prisoner status inability to participate in a standard post-operative follow-up visit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Blood Glucose Measurement<br>Subjects have sensors placed on skin before surgery and these sensors will measure the subject's glucose until the third day after surgery when they are removed. | Device: Continuous glucose monitoring system<br>* one or two monitors will be placed in the tissue to be transferred<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perfusion and tissue transfer outcome during reconstructive surgery predicted by continuous glucose monitoring of tissue |  | Up to three days post-op | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tissue perfusion, reconstructive surgery, continuous glucose monitoring
Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa

Study Overview
=================
Brief Summary
-----------------
Male and female patients aged ≥ 30 years with advanced stage idiopathic Parkinson's disease, not well controlled on existing levodopa will take part in a research study at approximately 82 sites in Europe, Israel, South Africa, Australia and new Zealand. The purpose of the study is to evaluate the effectiveness, safety and tolerability of the rotigotine patch (SPM 962) at an individual patient's optimal dose for a period of 4 months Each patient who qualifies and chooses to participate in the study will receive either rotigotine, pramipexole, or placebo at gradually increasing doses over a period of up to 7 weeks, and then maintain their optimal dose for 4 months. The study clinic visits will include a medical history and physical exam, ECG, blood and urine sample collection, completion of various questionnaires, and completion of a diary to record the severity of their Parkinson's symptoms. Patients who complete the study may enroll in an extension trial and receive active study drug.

Official Title
-----------------
A Multi-centre, Multi-national, Phase 3, Randomized, Double-blind, Double-dummy, 3- Arm Parallel Group, Placebo- and Pramipexole- Controlled Trial of the Efficacy and Safety of Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa

Conditions
-----------------
Parkinson Disease, Idiopathic

Intervention / Treatment
-----------------
* Drug: SPM 962


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced stage idiopathic Parkinson's disease Exclusion Criteria: Well controlled on levodopa

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: SPM 962|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
advanced stage idiopathic Parkinson's disease
Assessing Cement-bone Incorporation and Adjacent Segment Degeneration Following Cement Augmentation; an MRI-PET Follow-up

Study Overview
=================
Brief Summary
-----------------
3-year PET-MRI follow-up after vertebral balloon kyphoplasty aiming to investigate cement incorporation.

Official Title
-----------------
Assessing Cement-bone Incorporation and Adjacent Segment Degeneration Following Cement Augmentation; an MRI-PET Follow-up

Conditions
-----------------
Vertebral Fracture, Cement Augmentation

Intervention / Treatment
-----------------
* Diagnostic Test: PET MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Men and women aged 18 to 70 years Minimum 3-year follow-up Single-level vertebral kyphoplasty Index surgery at UniversitätsSpital Zürich MRI-scan during initial treatment Informed consent provided Exclusion criteria Combined with other operative procedure on the spine (e.g. dorsal instrumentation) Intraoperative intradiscal cement leakage Previous history of spinal surgery except on the cervical spine Metastatic disease with skeletal involvement Known chronic diseases of the bone metabolism other than osteoporosis Documented pregnancy (see also 6.3) Presence of implants not suited for MRI (pacemaker, neuro-stimulators, pain pumps, insulin pumps, Cochlea implants, metallic foreign bodies like bullet fragments)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: Prospective PET-MRI follow-up
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: PET MRI|18F-fluoride PET-MRI|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tracer Uptake | Perifokal tracer uptake at the cement-bone border | at least 3 years after kyphoplasty | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intravertebral Discs | Tracer uptake within the intravertebral disc and morphological changes | at least 3 years after kyphoplasty |
Novel Biomarkers in Chronic Airway Diseases

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is: To define The differences of bio-chemical phenotypes in chronic airway inflammatory diseases. To identify novel biomarkers in chronic airway inflammatory diseases as a screening, diagnostic, or monitoring marker.

Official Title
-----------------
The Study for The Identification of Novel Biomarkers in Chronic Airway Inflammatory Disorders

Conditions
-----------------
Asthma, COPD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years olds Both sexes Asthma or COPD was diagnosed according to the criteria of the American Thoracic Society, GINA, GOLD guideline Acute exacerbation was defined by the criteria of the American Thoracic Society, GINA, GOLD guideline For stable disease, none of the subjects had received inhaled or oral corticosteroids or any other anti-inflammatory drugs, had an exacerbation history in the previous 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute exacerbation<br> | |
| Stable disease<br> | |
| Healthy control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs

Study Overview
=================
Brief Summary
-----------------
This study will examine the epidemiology (incidence and control of a disease), burden, clinical need, and treatment patterns of spasticity in patients with a diagnosis of Cerebral Palsy (CP), Multiple Sclerosis (MS), Stroke, Spinal Cord Injury (SCI), or Traumatic Brain Injury (TBI).

Conditions
-----------------
Muscle Spasticity

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Diagnosis of Cerebral Palsy (CP), Multiple Sclerosis (MS), Stroke, Spinal Cord Injury (SCI), or Traumatic Brain Injury (TBI) for a minimum of 3 months Exclusion Criteria: -Participation in a spasticity clinical trial in the past 5 years.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Participants<br>Patients with a diagnosis of CP, MS, Stroke, SCI, or TBI will be evaluated for spasticity by their healthcare provider. Patients diagnosed with spasticity requiring treatment will be enrolled in the study. There is no intervention administered in this study. | Other: No Intervention<br>* There is no intervention administered in this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Investigator Assessment of Spasticity Severity using a 5-Point Scale |  | Day 1 | 
| Percentage of Participants with Spasticity not Receiving Treatment |  | Day 1 | 
| Spasticity Symptom Assessment Score using a 21-item Questionnaire |  | Day 1 | 
| Spasticity Impact Assessment Score using a 32-item Questionnaire |  | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants with Spasticity Receiving Treatment |  | Day 1 | 
| Referral Patterns for Spasticity Management |  | Day 1 | 
| Spasticity Screening Tool Score using a 13-item Questionnaire |  | Day 1 |
A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Study Overview
=================
Brief Summary
-----------------
Growth hormone secreting pituitary adenomas(GHomas) produce excessive GH, stimulating excessive insulin like growth factor 1(IGF-1) synthesis in the liver, thus causing multiple systemic complications. The life expectancy of patients with untreated GHomas is shortened by ten years. The treatment goal of GHomas is to shrink the tumor volume and normalize GH and IGF-1. Under current treatment, only 50-70% of patients get remission. Rosiglitazone is a widely used oral antidiabetic medicine. The investigator's preliminary data showed that rosiglitazone decreased the synthesis of GH and IGF-1 in rat pituitary tumor cells GH3 and hepatocytes respectively. The investigator plan to investigate the efficacy of rosiglitazone in the treatment of patients with GHomas who have not been alleviated by other therapies.

Official Title
-----------------
A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Conditions
-----------------
Pituitary Tumor

Intervention / Treatment
-----------------
* Drug: Rosiglitazone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with GHomas confirmed by surgery Patients who did not get biochemical remission: GH nadir after oral glucose tolerance test（OGTT）>1.0ug/L or IGF-1 exceeds age matched normal range Exclusion Criteria: Patients who were allergic to rosiglitazone Patients with liver or kidney dysfunction, respiratory failure Patients with heart failure Patients with edema Patients with severe hyperlipidemia Patients with osteoporosis or a history of non traumatic fractures Patients with pregnancy and lactation Patients who had received radiation therapy within 3 years Patients who had participated in other clinical trials within 3 months Patients with other neoplastic diseases Patients with mental and neurological disorders Patients with other conditions which were believed not appropriate to take part in the clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ros<br>Rosiglitazone：2 times a day, 4mg each time（4mgBid） | Drug: Rosiglitazone<br>* rosiglitazone is added to the primary treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Growth hormone(GH) | the decrease of growth hormone(GH) | 6 months | 
| insulin like factor 1(IGF-1) | the decrease of insulin like factor 1(IGF-1) | 6 months | 
| tumor volume | the change of tumor volume | 6 months |
Patient-Centered Smartphone-Based Diabetes Care

Study Overview
=================
Brief Summary
-----------------
The investigators developed a patient-centered smartphone-based diabetes care system (PSDCS). This study was aimed to test the feasibility of the PSDCS.

Official Title
-----------------
Feasibility of a Patient-Centered Smartphone-Based Diabetes Care System: a Pilot Study

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: patient-centered smartphone-based diabetes care system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: type 2 diabetes HbA1c levels ≥ 6.5% Exclusion Criteria: severe diabetic complication including severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy, chronic kidney disease stage 4-5, severe diabetic neuropathy, history of diabetic foot, history of angina pectoris, myocardial infarction, and cerebrovascular disease, and peripheral arterial disease type 1 diabetes insulin therapy other than insulin glargine subjects with insulin pump history of drug addiction history of psychotic disorder pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PSDCS<br>using the patient-centered smartphone-based diabetes care system (PSDCS) for 12 weeks | Device: patient-centered smartphone-based diabetes care system<br>* patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of HbA1c |  | baseline and the end of 12 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of fasting plasma glucose |  | baseline and after 12 weeks (within 3 days) | 
| change of lipid profile |  | baseline and after 12 weeks (within 3 days) | 
| change of body weight |  | baseline and after 12 weeks (within 3 days) | 
| change of the scores of Summary of Diabetes Self-Care Activities (SDSCA) |  | baseline and after 12 weeks (within 3 days) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Health care systems, Mobile applications, Self-care, Diabetes mellitus, Smartphone
Effect of the Intensity of Continuous Renal Replacement Therapy

Study Overview
=================
Brief Summary
-----------------
In patients with sepsis and AKI, increasing the intensity of renal replacement therapy from 50 mL/kg/h (HVHF) to 85 mL/kg/h (EHVHF)will increase the survival at 28 days and 90 days.

Official Title
-----------------
Effect of the Intensity of Continuous Renal Replacement Therapy in Patients With Sepsis and Acute Kidney Injury: Single-center Randomized Clinical Trial

Conditions
-----------------
Optimal Intensity of Renal Replacement Therapy on Sepsis Patients

Intervention / Treatment
-----------------
* Other: extra high volume hemofiltration
* Other: high volume hemofiltration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: met at least one of the following criteria: oliguria (urine output less than 100 mL in a 6 h period and unresponsive to fluid resuscitation), serum potassium concentration more than 6.5 mmol/L, severe acidemia (pH < 7.2), serum creatinine more than 250 µmol/L, or presence of severe organ edema (e.g. pulmonary edema). Exclusion Criteria: were presence of a malignant tumor, chronic renal insufficiency (serum creatinine >133 µmol/L), or receiving any kind of renal replacement therapy before randomization.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: extra high volume hemofiltration<br>extra high volume hemofiltration (85 mL/kg/h, EHVHF) | Other: extra high volume hemofiltration<br>* extra high volume hemofiltration (85 mL/kg/h, EHVHF)<br>|
| Sham Comparator: high volume hemofiltration<br>high volume hemofiltration (50 mL/kg/h, HVHF) | Other: high volume hemofiltration<br>* high volume hemofiltration (50 mL/kg/h, HVHF)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 90 days survival | The primary study outcome was death from any cause within 90 days. Results were analyzed by Kaplan-Meier survival curves |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of stay in the ICU and hospital | Secondary outcomes were length of stay in the ICU and hospital and renal outcome of survivors at 90 days after randomization. |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
high volume hemofiltration, sepsis, acute kidney injury, survival